Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Tubules, Proximal | 13 | 2023 | 25 | 3.210 |
Why?
|
Models, Biological | 7 | 2024 | 1177 | 1.650 |
Why?
|
Kidney | 10 | 2023 | 444 | 1.600 |
Why?
|
Kidney Diseases | 4 | 2022 | 174 | 1.530 |
Why?
|
Intestinal Mucosa | 3 | 2025 | 240 | 1.230 |
Why?
|
Drug Evaluation, Preclinical | 6 | 2025 | 96 | 1.190 |
Why?
|
Organoids | 2 | 2025 | 42 | 1.160 |
Why?
|
Syndecan-1 | 2 | 2024 | 9 | 1.140 |
Why?
|
Corneal Dystrophies, Hereditary | 3 | 2017 | 3 | 1.110 |
Why?
|
Retinal Diseases | 3 | 2017 | 33 | 1.060 |
Why?
|
Liver | 11 | 2020 | 833 | 1.050 |
Why?
|
Plasma | 2 | 2024 | 37 | 1.010 |
Why?
|
Cytochrome P-450 CYP3A | 5 | 2024 | 12 | 1.000 |
Why?
|
Trauma Centers | 6 | 2022 | 118 | 0.940 |
Why?
|
Rats, Sprague-Dawley | 4 | 2024 | 618 | 0.930 |
Why?
|
Burns | 1 | 2024 | 41 | 0.870 |
Why?
|
Resuscitation | 1 | 2024 | 66 | 0.860 |
Why?
|
Toxicity Tests | 3 | 2017 | 18 | 0.810 |
Why?
|
Epithelial Cells | 6 | 2020 | 388 | 0.810 |
Why?
|
Wounds and Injuries | 4 | 2018 | 237 | 0.770 |
Why?
|
Cytochrome P-450 Enzyme System | 5 | 2021 | 28 | 0.770 |
Why?
|
Acute Kidney Injury | 4 | 2023 | 142 | 0.760 |
Why?
|
Drug Discovery | 3 | 2021 | 94 | 0.740 |
Why?
|
Cytochrome P450 Family 4 | 4 | 2021 | 4 | 0.720 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2024 | 58 | 0.710 |
Why?
|
Prescription Drugs | 1 | 2021 | 51 | 0.710 |
Why?
|
Ochratoxins | 1 | 2020 | 1 | 0.700 |
Why?
|
Disease Models, Animal | 3 | 2024 | 2161 | 0.690 |
Why?
|
Oligonucleotides, Antisense | 1 | 2021 | 142 | 0.640 |
Why?
|
Polymyxins | 1 | 2018 | 1 | 0.620 |
Why?
|
Cell Culture Techniques | 6 | 2020 | 182 | 0.580 |
Why?
|
Humans | 66 | 2025 | 62378 | 0.550 |
Why?
|
Retinal Pigment Epithelium | 1 | 2017 | 35 | 0.540 |
Why?
|
Life Support Care | 1 | 2017 | 20 | 0.530 |
Why?
|
Renal Elimination | 1 | 2016 | 3 | 0.530 |
Why?
|
Biological Transport | 7 | 2024 | 295 | 0.520 |
Why?
|
General Surgery | 3 | 2016 | 201 | 0.520 |
Why?
|
Intestinal Absorption | 3 | 2025 | 30 | 0.520 |
Why?
|
Forecasting | 1 | 2017 | 230 | 0.520 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 531 | 0.510 |
Why?
|
Lab-On-A-Chip Devices | 3 | 2020 | 23 | 0.480 |
Why?
|
Biomarkers | 6 | 2024 | 1376 | 0.480 |
Why?
|
Respiratory Insufficiency | 1 | 2017 | 154 | 0.460 |
Why?
|
Pharmaceutical Preparations | 4 | 2025 | 123 | 0.430 |
Why?
|
Traumatology | 2 | 2016 | 8 | 0.430 |
Why?
|
Cell Line | 8 | 2021 | 2033 | 0.420 |
Why?
|
Rats | 8 | 2024 | 1974 | 0.410 |
Why?
|
Mutation | 2 | 2021 | 2573 | 0.400 |
Why?
|
DNA | 2 | 2017 | 840 | 0.400 |
Why?
|
Space Flight | 2 | 2022 | 18 | 0.400 |
Why?
|
Animals | 21 | 2025 | 20495 | 0.390 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2023 | 128 | 0.380 |
Why?
|
Ichthyosis, Lamellar | 1 | 2011 | 1 | 0.370 |
Why?
|
Cisplatin | 3 | 2020 | 138 | 0.360 |
Why?
|
Hepatocytes | 5 | 2020 | 214 | 0.350 |
Why?
|
Zinc | 1 | 2011 | 92 | 0.340 |
Why?
|
Emergency Medicine | 1 | 2012 | 188 | 0.330 |
Why?
|
Drug Interactions | 3 | 2025 | 127 | 0.320 |
Why?
|
Hepatitis A Virus Cellular Receptor 1 | 2 | 2019 | 3 | 0.320 |
Why?
|
Education, Medical, Graduate | 1 | 2012 | 337 | 0.310 |
Why?
|
Cytochrome P-450 CYP2D6 | 4 | 2016 | 7 | 0.310 |
Why?
|
Hypoglycemic Agents | 2 | 2025 | 213 | 0.300 |
Why?
|
Membrane Transport Proteins | 3 | 2023 | 131 | 0.300 |
Why?
|
Metformin | 2 | 2025 | 71 | 0.300 |
Why?
|
Blood-Brain Barrier | 2 | 2023 | 82 | 0.290 |
Why?
|
Intestine, Small | 2 | 2020 | 79 | 0.290 |
Why?
|
Heme Oxygenase-1 | 2 | 2018 | 19 | 0.280 |
Why?
|
Intestinal Obstruction | 2 | 2019 | 53 | 0.280 |
Why?
|
Administration, Oral | 2 | 2025 | 365 | 0.270 |
Why?
|
Male | 26 | 2025 | 29308 | 0.270 |
Why?
|
Emergencies | 3 | 2019 | 116 | 0.270 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 782 | 0.260 |
Why?
|
Endothelium, Vascular | 2 | 2024 | 175 | 0.260 |
Why?
|
Organic Anion Transporters | 2 | 2023 | 6 | 0.250 |
Why?
|
Pregnancy | 5 | 2019 | 2304 | 0.250 |
Why?
|
Terpenes | 2 | 2016 | 27 | 0.250 |
Why?
|
Female | 28 | 2025 | 32310 | 0.240 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2015 | 11 | 0.240 |
Why?
|
Thrombomodulin | 1 | 2024 | 17 | 0.230 |
Why?
|
Enterocytes | 1 | 2024 | 24 | 0.230 |
Why?
|
Glycocalyx | 1 | 2024 | 3 | 0.230 |
Why?
|
Human Umbilical Vein Endothelial Cells | 2 | 2021 | 39 | 0.220 |
Why?
|
Shock | 1 | 2024 | 33 | 0.220 |
Why?
|
Microsomes, Liver | 2 | 2021 | 21 | 0.210 |
Why?
|
RNA, Messenger | 5 | 2016 | 1519 | 0.210 |
Why?
|
Cells, Cultured | 7 | 2024 | 2148 | 0.200 |
Why?
|
Kidney Tubules | 2 | 2022 | 21 | 0.200 |
Why?
|
Weightlessness | 1 | 2022 | 11 | 0.200 |
Why?
|
Pneumococcal Infections | 1 | 2022 | 38 | 0.200 |
Why?
|
Cystic Fibrosis | 1 | 2023 | 118 | 0.200 |
Why?
|
Pilots | 1 | 2022 | 9 | 0.200 |
Why?
|
Gentamicins | 2 | 2019 | 25 | 0.200 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2022 | 16 | 0.200 |
Why?
|
Surgical Procedures, Operative | 3 | 2015 | 139 | 0.200 |
Why?
|
Computer Simulation | 2 | 2022 | 476 | 0.200 |
Why?
|
Hospitals, Community | 1 | 2022 | 71 | 0.200 |
Why?
|
Middle Aged | 15 | 2024 | 17269 | 0.200 |
Why?
|
Polymyxin B | 2 | 2018 | 9 | 0.190 |
Why?
|
Air Ambulances | 1 | 2022 | 26 | 0.190 |
Why?
|
Hepatitis C | 2 | 2016 | 150 | 0.190 |
Why?
|
Appendicitis | 1 | 2022 | 78 | 0.190 |
Why?
|
Xenobiotics | 2 | 2018 | 13 | 0.190 |
Why?
|
G-Quadruplexes | 1 | 2021 | 6 | 0.180 |
Why?
|
Adult | 16 | 2025 | 16549 | 0.180 |
Why?
|
Postoperative Complications | 3 | 2022 | 1261 | 0.180 |
Why?
|
Aldehyde Oxidase | 1 | 2020 | 1 | 0.180 |
Why?
|
Morpholinos | 1 | 2021 | 52 | 0.180 |
Why?
|
Glucuronosyltransferase | 1 | 2020 | 11 | 0.180 |
Why?
|
Sulfotransferases | 1 | 2020 | 8 | 0.180 |
Why?
|
HEK293 Cells | 2 | 2021 | 614 | 0.180 |
Why?
|
Cell Survival | 3 | 2018 | 572 | 0.180 |
Why?
|
Carboxylic Ester Hydrolases | 1 | 2020 | 11 | 0.180 |
Why?
|
Organic Cation Transport Proteins | 3 | 2020 | 4 | 0.170 |
Why?
|
Membrane Proteins | 2 | 2016 | 882 | 0.170 |
Why?
|
Intestines | 1 | 2021 | 164 | 0.170 |
Why?
|
Vitamin D | 2 | 2018 | 139 | 0.170 |
Why?
|
Flame Retardants | 1 | 2020 | 6 | 0.170 |
Why?
|
Halogenated Diphenyl Ethers | 1 | 2020 | 9 | 0.170 |
Why?
|
Renal Reabsorption | 1 | 2019 | 1 | 0.170 |
Why?
|
Drug Antagonism | 1 | 2019 | 9 | 0.170 |
Why?
|
Desogestrel | 1 | 2019 | 4 | 0.170 |
Why?
|
Benzoxazines | 1 | 2019 | 11 | 0.160 |
Why?
|
Levonorgestrel | 1 | 2019 | 10 | 0.160 |
Why?
|
Surgeons | 1 | 2022 | 173 | 0.160 |
Why?
|
Tissue Culture Techniques | 1 | 2019 | 36 | 0.160 |
Why?
|
Retrospective Studies | 8 | 2024 | 6481 | 0.160 |
Why?
|
Iohexol | 1 | 2019 | 16 | 0.160 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 761 | 0.160 |
Why?
|
Gastrointestinal Tract | 1 | 2021 | 178 | 0.160 |
Why?
|
Contraceptive Agents, Female | 1 | 2019 | 24 | 0.160 |
Why?
|
Kidney Tubular Necrosis, Acute | 1 | 2019 | 5 | 0.160 |
Why?
|
Critical Pathways | 1 | 2019 | 32 | 0.160 |
Why?
|
Rifampin | 1 | 2019 | 25 | 0.160 |
Why?
|
Aged | 14 | 2024 | 14184 | 0.160 |
Why?
|
Digestive System Diseases | 1 | 2019 | 14 | 0.160 |
Why?
|
Dehydrocholesterols | 1 | 2018 | 1 | 0.160 |
Why?
|
Desmosterol | 1 | 2018 | 2 | 0.160 |
Why?
|
Lanosterol | 1 | 2018 | 4 | 0.160 |
Why?
|
Emergency Medical Services | 1 | 2022 | 260 | 0.150 |
Why?
|
Microsomes | 2 | 2016 | 11 | 0.150 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2018 | 25 | 0.150 |
Why?
|
Low Density Lipoprotein Receptor-Related Protein-2 | 1 | 2018 | 2 | 0.150 |
Why?
|
Myocardium | 1 | 2020 | 273 | 0.150 |
Why?
|
Gene Expression | 2 | 2018 | 834 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 859 | 0.150 |
Why?
|
Hospital Mortality | 4 | 2016 | 862 | 0.150 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 48 | 0.150 |
Why?
|
Lymphoma | 1 | 2019 | 101 | 0.150 |
Why?
|
Digestive System Surgical Procedures | 1 | 2019 | 90 | 0.150 |
Why?
|
Anti-HIV Agents | 1 | 2019 | 154 | 0.150 |
Why?
|
Aristolochic Acids | 1 | 2017 | 1 | 0.140 |
Why?
|
Enteral Nutrition | 1 | 2018 | 54 | 0.140 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2018 | 125 | 0.140 |
Why?
|
United States | 6 | 2022 | 7690 | 0.140 |
Why?
|
Graft vs Host Disease | 1 | 2019 | 110 | 0.140 |
Why?
|
Lung | 2 | 2020 | 937 | 0.140 |
Why?
|
Fundus Oculi | 1 | 2017 | 22 | 0.140 |
Why?
|
Electroretinography | 1 | 2017 | 26 | 0.140 |
Why?
|
RNA, Long Noncoding | 1 | 2020 | 169 | 0.140 |
Why?
|
Hydrocortisone | 1 | 2019 | 192 | 0.140 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 185 | 0.140 |
Why?
|
Genes, Recessive | 1 | 2017 | 52 | 0.140 |
Why?
|
Polymerase Chain Reaction | 2 | 2017 | 514 | 0.140 |
Why?
|
Patient Admission | 2 | 2016 | 189 | 0.140 |
Why?
|
Homozygote | 1 | 2017 | 123 | 0.140 |
Why?
|
Fluorescein Angiography | 1 | 2017 | 58 | 0.140 |
Why?
|
Referral and Consultation | 2 | 2022 | 420 | 0.140 |
Why?
|
Tissue Engineering | 1 | 2018 | 142 | 0.140 |
Why?
|
Pedigree | 1 | 2017 | 193 | 0.130 |
Why?
|
Specialties, Surgical | 1 | 2017 | 47 | 0.130 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 196 | 0.130 |
Why?
|
Kidney Cortex | 1 | 2016 | 10 | 0.130 |
Why?
|
Contrast Media | 1 | 2019 | 421 | 0.130 |
Why?
|
Glucuronides | 1 | 2016 | 11 | 0.130 |
Why?
|
Biological Transport, Active | 1 | 2016 | 37 | 0.130 |
Why?
|
Hepatitis C, Chronic | 1 | 2017 | 88 | 0.130 |
Why?
|
Visual Acuity | 1 | 2017 | 126 | 0.130 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2017 | 48 | 0.130 |
Why?
|
Hospitals, Low-Volume | 1 | 2016 | 18 | 0.130 |
Why?
|
Metoprolol | 1 | 2015 | 16 | 0.130 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2019 | 347 | 0.120 |
Why?
|
Blood Loss, Surgical | 1 | 2016 | 60 | 0.120 |
Why?
|
Hospitals, High-Volume | 1 | 2016 | 32 | 0.120 |
Why?
|
Health Services for the Aged | 1 | 2016 | 48 | 0.120 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2017 | 176 | 0.120 |
Why?
|
Homeostasis | 1 | 2018 | 363 | 0.120 |
Why?
|
Patient Care Planning | 1 | 2016 | 86 | 0.120 |
Why?
|
Proteome | 1 | 2016 | 150 | 0.120 |
Why?
|
Lactation | 1 | 2015 | 69 | 0.120 |
Why?
|
Erythrocyte Transfusion | 1 | 2016 | 72 | 0.120 |
Why?
|
Hemorrhage | 1 | 2017 | 266 | 0.120 |
Why?
|
Geriatric Assessment | 1 | 2016 | 163 | 0.120 |
Why?
|
State Government | 1 | 2015 | 31 | 0.120 |
Why?
|
Glyburide | 1 | 2014 | 9 | 0.120 |
Why?
|
Ultrasonography | 1 | 2017 | 470 | 0.120 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2015 | 153 | 0.120 |
Why?
|
Internship and Residency | 1 | 2022 | 781 | 0.120 |
Why?
|
Biocatalysis | 1 | 2015 | 46 | 0.120 |
Why?
|
Proline | 1 | 2015 | 44 | 0.120 |
Why?
|
Liver Neoplasms | 1 | 2017 | 293 | 0.120 |
Why?
|
Liver Cirrhosis | 1 | 2016 | 170 | 0.110 |
Why?
|
Morbidity | 1 | 2015 | 113 | 0.110 |
Why?
|
Venous Thromboembolism | 1 | 2016 | 147 | 0.110 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2014 | 41 | 0.110 |
Why?
|
Follow-Up Studies | 2 | 2017 | 2439 | 0.110 |
Why?
|
Survival Rate | 1 | 2017 | 837 | 0.110 |
Why?
|
Adrenal Cortex Hormones | 1 | 2016 | 173 | 0.110 |
Why?
|
Brain Injuries, Traumatic | 1 | 2016 | 93 | 0.110 |
Why?
|
Cell Membrane | 1 | 2016 | 494 | 0.110 |
Why?
|
Substrate Specificity | 2 | 2012 | 335 | 0.110 |
Why?
|
Models, Animal | 2 | 2012 | 235 | 0.110 |
Why?
|
Critical Care | 1 | 2017 | 389 | 0.110 |
Why?
|
Phenotype | 1 | 2017 | 1189 | 0.100 |
Why?
|
Ethanol | 1 | 2016 | 321 | 0.100 |
Why?
|
Blotting, Western | 1 | 2014 | 608 | 0.100 |
Why?
|
Aged, 80 and over | 6 | 2022 | 5386 | 0.100 |
Why?
|
Mice, Inbred C57BL | 3 | 2016 | 3370 | 0.100 |
Why?
|
Wounds, Nonpenetrating | 1 | 2013 | 107 | 0.100 |
Why?
|
Mice | 6 | 2023 | 10744 | 0.100 |
Why?
|
Accreditation | 1 | 2012 | 75 | 0.090 |
Why?
|
Lipids | 1 | 2014 | 315 | 0.090 |
Why?
|
Promoter Regions, Genetic | 2 | 2011 | 668 | 0.090 |
Why?
|
Cerebrospinal Fluid | 1 | 2011 | 20 | 0.090 |
Why?
|
Medicare | 1 | 2015 | 614 | 0.090 |
Why?
|
Fellowships and Scholarships | 1 | 2012 | 101 | 0.090 |
Why?
|
Cations, Divalent | 1 | 2011 | 23 | 0.090 |
Why?
|
Ion Transport | 1 | 2011 | 21 | 0.090 |
Why?
|
Citric Acid | 1 | 2011 | 18 | 0.090 |
Why?
|
Chelating Agents | 1 | 2011 | 50 | 0.090 |
Why?
|
Gene Knockout Techniques | 1 | 2011 | 95 | 0.090 |
Why?
|
Trace Elements | 1 | 2011 | 20 | 0.090 |
Why?
|
Caprylates | 2 | 2021 | 14 | 0.090 |
Why?
|
Health Services Needs and Demand | 1 | 2012 | 207 | 0.090 |
Why?
|
Proteomics | 3 | 2017 | 283 | 0.090 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 173 | 0.090 |
Why?
|
DNA, Viral | 1 | 2011 | 231 | 0.080 |
Why?
|
Pyridines | 1 | 2011 | 111 | 0.080 |
Why?
|
Young Adult | 5 | 2020 | 4603 | 0.080 |
Why?
|
Fatty Acids | 1 | 2011 | 200 | 0.080 |
Why?
|
Cytochrome P-450 CYP4A | 1 | 2009 | 1 | 0.080 |
Why?
|
Feasibility Studies | 2 | 2022 | 561 | 0.080 |
Why?
|
Fluorescent Dyes | 1 | 2011 | 198 | 0.080 |
Why?
|
Pilot Projects | 2 | 2022 | 976 | 0.080 |
Why?
|
Diaphragmatic Eventration | 1 | 2008 | 2 | 0.080 |
Why?
|
Rabbits | 3 | 2016 | 331 | 0.080 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2009 | 131 | 0.080 |
Why?
|
Stress, Physiological | 1 | 2011 | 191 | 0.080 |
Why?
|
Intracranial Hemorrhage, Traumatic | 1 | 2008 | 9 | 0.080 |
Why?
|
Length of Stay | 3 | 2019 | 796 | 0.080 |
Why?
|
Adolescent | 5 | 2020 | 6132 | 0.080 |
Why?
|
Prospective Studies | 3 | 2023 | 3245 | 0.070 |
Why?
|
Oxidation-Reduction | 2 | 2021 | 324 | 0.070 |
Why?
|
Multidrug Resistance-Associated Proteins | 2 | 2017 | 16 | 0.070 |
Why?
|
Mice, Transgenic | 1 | 2011 | 1265 | 0.070 |
Why?
|
Accidental Falls | 1 | 2008 | 128 | 0.070 |
Why?
|
Organic Cation Transporter 2 | 2 | 2020 | 3 | 0.070 |
Why?
|
Genotype | 3 | 2015 | 648 | 0.060 |
Why?
|
California | 2 | 2016 | 174 | 0.060 |
Why?
|
Nelfinavir | 1 | 2005 | 7 | 0.060 |
Why?
|
Risk Factors | 4 | 2016 | 5283 | 0.060 |
Why?
|
Tandem Mass Spectrometry | 2 | 2017 | 146 | 0.060 |
Why?
|
Creatinine | 2 | 2019 | 134 | 0.060 |
Why?
|
Genes, MDR | 1 | 2005 | 3 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2019 | 5553 | 0.060 |
Why?
|
Dextrorphan | 2 | 2016 | 2 | 0.060 |
Why?
|
Dextromethorphan | 2 | 2016 | 3 | 0.060 |
Why?
|
Duodenum | 1 | 2024 | 42 | 0.060 |
Why?
|
HIV Protease Inhibitors | 1 | 2005 | 105 | 0.060 |
Why?
|
Aminoglycosides | 1 | 2023 | 11 | 0.050 |
Why?
|
Introns | 2 | 2020 | 108 | 0.050 |
Why?
|
Fluorescein | 1 | 2023 | 13 | 0.050 |
Why?
|
Anions | 1 | 2023 | 33 | 0.050 |
Why?
|
fas Receptor | 1 | 2023 | 57 | 0.050 |
Why?
|
Risk Assessment | 2 | 2024 | 2033 | 0.050 |
Why?
|
Urinary Catheterization | 1 | 2003 | 20 | 0.050 |
Why?
|
RNA Precursors | 1 | 2004 | 74 | 0.050 |
Why?
|
Spacecraft | 1 | 2022 | 6 | 0.050 |
Why?
|
Splenectomy | 1 | 2022 | 41 | 0.050 |
Why?
|
Child | 3 | 2020 | 4415 | 0.050 |
Why?
|
Aircraft | 1 | 2022 | 18 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 542 | 0.050 |
Why?
|
Appendectomy | 1 | 2022 | 52 | 0.050 |
Why?
|
Urinary Tract Infections | 1 | 2003 | 89 | 0.050 |
Why?
|
Proteinuria | 1 | 2022 | 41 | 0.050 |
Why?
|
Blood Proteins | 1 | 2022 | 76 | 0.050 |
Why?
|
Milk, Human | 2 | 2015 | 90 | 0.050 |
Why?
|
Cross Infection | 1 | 2003 | 160 | 0.050 |
Why?
|
Fatigue | 1 | 2022 | 112 | 0.050 |
Why?
|
Patient Readmission | 2 | 2016 | 427 | 0.050 |
Why?
|
Kinetics | 1 | 2023 | 763 | 0.050 |
Why?
|
Spleen | 1 | 2022 | 482 | 0.050 |
Why?
|
Postpartum Period | 2 | 2015 | 194 | 0.040 |
Why?
|
Cimetidine | 1 | 2020 | 3 | 0.040 |
Why?
|
Biological Availability | 1 | 2021 | 200 | 0.040 |
Why?
|
Retinoid X Receptor alpha | 1 | 2020 | 8 | 0.040 |
Why?
|
Cadmium | 1 | 2019 | 13 | 0.040 |
Why?
|
Carbohydrate Metabolism | 1 | 2020 | 49 | 0.040 |
Why?
|
Nevirapine | 1 | 2019 | 8 | 0.040 |
Why?
|
Pharmacogenomic Testing | 1 | 2019 | 7 | 0.040 |
Why?
|
PPAR alpha | 1 | 2020 | 34 | 0.040 |
Why?
|
Uganda | 1 | 2019 | 39 | 0.040 |
Why?
|
Historically Controlled Study | 1 | 2019 | 1 | 0.040 |
Why?
|
Alkynes | 1 | 2019 | 24 | 0.040 |
Why?
|
Tissue Donors | 1 | 2020 | 153 | 0.040 |
Why?
|
Kenya | 1 | 2019 | 81 | 0.040 |
Why?
|
Radiography, Abdominal | 1 | 2019 | 26 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2019 | 49 | 0.040 |
Why?
|
Fluorocarbons | 1 | 2019 | 38 | 0.040 |
Why?
|
Receptors, Glucocorticoid | 1 | 2019 | 27 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 147 | 0.040 |
Why?
|
Prognosis | 1 | 2023 | 1715 | 0.040 |
Why?
|
Technology Transfer | 1 | 2018 | 4 | 0.040 |
Why?
|
Regenerative Medicine | 1 | 2018 | 20 | 0.040 |
Why?
|
Collagen Type I | 1 | 2018 | 41 | 0.040 |
Why?
|
Animal Testing Alternatives | 1 | 2018 | 1 | 0.040 |
Why?
|
Linear Models | 1 | 2019 | 408 | 0.040 |
Why?
|
Gene Knockdown Techniques | 1 | 2019 | 200 | 0.040 |
Why?
|
Lipid Metabolism | 1 | 2020 | 220 | 0.040 |
Why?
|
High-Throughput Screening Assays | 1 | 2018 | 78 | 0.040 |
Why?
|
Dicumarol | 1 | 2017 | 1 | 0.040 |
Why?
|
Nephrons | 1 | 2017 | 7 | 0.040 |
Why?
|
Biotransformation | 1 | 2017 | 23 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2017 | 11 | 0.040 |
Why?
|
Up-Regulation | 1 | 2019 | 372 | 0.040 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 1 | 2017 | 44 | 0.040 |
Why?
|
Carcinogens | 1 | 2017 | 37 | 0.040 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2017 | 37 | 0.040 |
Why?
|
Tissue Scaffolds | 1 | 2018 | 85 | 0.040 |
Why?
|
Clinical Competence | 1 | 2022 | 710 | 0.040 |
Why?
|
Endocytosis | 1 | 2018 | 152 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2017 | 130 | 0.030 |
Why?
|
Models, Theoretical | 1 | 2019 | 271 | 0.030 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2017 | 4 | 0.030 |
Why?
|
Hepatocyte Nuclear Factor 4 | 1 | 2017 | 7 | 0.030 |
Why?
|
Aflatoxin B1 | 1 | 2017 | 7 | 0.030 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2017 | 13 | 0.030 |
Why?
|
Cell Cycle | 1 | 2018 | 388 | 0.030 |
Why?
|
Abbreviated Injury Scale | 1 | 2016 | 13 | 0.030 |
Why?
|
Brain | 1 | 2005 | 1542 | 0.030 |
Why?
|
Macaca fascicularis | 1 | 2016 | 47 | 0.030 |
Why?
|
Failure to Rescue, Health Care | 1 | 2016 | 5 | 0.030 |
Why?
|
Geriatrics | 1 | 2016 | 43 | 0.030 |
Why?
|
Species Specificity | 1 | 2016 | 334 | 0.030 |
Why?
|
Cattle | 1 | 2016 | 308 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 104 | 0.030 |
Why?
|
Genes, Transgenic, Suicide | 1 | 2015 | 2 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2015 | 115 | 0.030 |
Why?
|
Child, Preschool | 1 | 2020 | 1915 | 0.030 |
Why?
|
Boston | 1 | 2016 | 251 | 0.030 |
Why?
|
Dogs | 1 | 2016 | 324 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2015 | 26 | 0.030 |
Why?
|
Enzyme Stability | 1 | 2015 | 47 | 0.030 |
Why?
|
Dexamethasone | 1 | 2016 | 205 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2022 | 1064 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2018 | 974 | 0.030 |
Why?
|
Protein Engineering | 1 | 2015 | 82 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2014 | 231 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2015 | 369 | 0.030 |
Why?
|
Trauma Severity Indices | 1 | 2013 | 34 | 0.030 |
Why?
|
Multiple Trauma | 1 | 2013 | 27 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2013 | 73 | 0.030 |
Why?
|
Health Services Research | 1 | 2015 | 270 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2015 | 928 | 0.030 |
Why?
|
Placenta | 1 | 2013 | 58 | 0.030 |
Why?
|
Retinoic Acid Receptor alpha | 1 | 2012 | 4 | 0.030 |
Why?
|
Retinoic Acid 4-Hydroxylase | 1 | 2012 | 4 | 0.030 |
Why?
|
Cytochrome P450 Family 2 | 1 | 2012 | 2 | 0.030 |
Why?
|
Hydroxylation | 1 | 2012 | 9 | 0.030 |
Why?
|
Enzyme Induction | 1 | 2012 | 45 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 1600 | 0.030 |
Why?
|
New England | 1 | 2013 | 271 | 0.030 |
Why?
|
Gestational Age | 1 | 2013 | 188 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2019 | 892 | 0.030 |
Why?
|
Comorbidity | 1 | 2016 | 1117 | 0.030 |
Why?
|
Response Elements | 1 | 2012 | 44 | 0.030 |
Why?
|
Intensive Care Units | 1 | 2016 | 403 | 0.030 |
Why?
|
Tretinoin | 1 | 2012 | 51 | 0.020 |
Why?
|
Receptors, Retinoic Acid | 1 | 2012 | 55 | 0.020 |
Why?
|
Databases, Factual | 1 | 2016 | 851 | 0.020 |
Why?
|
Logistic Models | 1 | 2016 | 1272 | 0.020 |
Why?
|
HIV Infections | 1 | 2019 | 960 | 0.020 |
Why?
|
Incidence | 1 | 2016 | 1359 | 0.020 |
Why?
|
Age Factors | 1 | 2016 | 1552 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2011 | 49 | 0.020 |
Why?
|
von Willebrand Factor | 1 | 2011 | 8 | 0.020 |
Why?
|
Lac Operon | 1 | 2011 | 26 | 0.020 |
Why?
|
Choroid Plexus | 1 | 2011 | 16 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2014 | 1592 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 1988 | 0.020 |
Why?
|
Integrases | 1 | 2011 | 37 | 0.020 |
Why?
|
Organ Specificity | 1 | 2011 | 190 | 0.020 |
Why?
|
Pregnancy Trimesters | 1 | 2010 | 10 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2010 | 49 | 0.020 |
Why?
|
Binding Sites | 1 | 2012 | 898 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2015 | 1004 | 0.020 |
Why?
|
Fetal Blood | 1 | 2010 | 72 | 0.020 |
Why?
|
Hepacivirus | 1 | 2011 | 141 | 0.020 |
Why?
|
Cytochrome P-450 Enzyme Inhibitors | 1 | 2009 | 4 | 0.020 |
Why?
|
Area Under Curve | 1 | 2010 | 146 | 0.020 |
Why?
|
Spodoptera | 1 | 2009 | 28 | 0.020 |
Why?
|
Baculoviridae | 1 | 2009 | 25 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2011 | 365 | 0.020 |
Why?
|
Lens, Crystalline | 1 | 2009 | 17 | 0.020 |
Why?
|
Amidines | 1 | 2009 | 19 | 0.020 |
Why?
|
Retinal Degeneration | 1 | 2009 | 27 | 0.020 |
Why?
|
Genetic Variation | 1 | 2011 | 370 | 0.020 |
Why?
|
Positive-Pressure Respiration | 1 | 2008 | 48 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2009 | 698 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 3735 | 0.020 |
Why?
|
Tetrahydroisoquinolines | 1 | 2005 | 1 | 0.020 |
Why?
|
Acridines | 1 | 2005 | 2 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2010 | 1335 | 0.020 |
Why?
|
Electrophoresis, Agar Gel | 1 | 2005 | 16 | 0.010 |
Why?
|
Blotting, Southern | 1 | 2005 | 55 | 0.010 |
Why?
|
Molecular Weight | 1 | 2005 | 187 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2005 | 291 | 0.010 |
Why?
|
Lymphocytes | 1 | 2005 | 195 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2005 | 406 | 0.010 |
Why?
|
Catheters, Indwelling | 1 | 2003 | 69 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2005 | 482 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 1436 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2005 | 2085 | 0.010 |
Why?
|